Amphastar Pharmaceuticals, Inc.

NasdaqGS AMPH

Amphastar Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 727.68 M

Amphastar Pharmaceuticals, Inc. Shareholders' Equity is USD 727.68 M for the quarter ending September 30, 2024, a 22.27% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Amphastar Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 595.14 M, a 17.81% change year over year.
  • Amphastar Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 505.17 M, a 17.43% change year over year.
  • Amphastar Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 430.18 M, a 6.16% change year over year.
  • Amphastar Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2020 was USD 405.23 M, a 4.06% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
NasdaqGS: AMPH

Amphastar Pharmaceuticals, Inc.

CEO Dr. Yongfeng Zhang Ph.D.
IPO Date June 25, 2014
Location United States
Headquarters 11570 6th Street
Employees 1,761
Sector Health Care
Industries
Description

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Similar companies

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

EOLS

Evolus, Inc.

USD 9.47

-3.37%

NBIX

Neurocrine Biosciences, Inc.

USD 139.51

-2.46%

ALKS

Alkermes plc

USD 28.50

0.53%

PCRX

Pacira BioSciences, Inc.

USD 20.55

-2.74%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

SUPN

Supernus Pharmaceuticals, Inc.

USD 37.82

0.66%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

StockViz Staff

January 15, 2025

Any question? Send us an email